title: Circulating glycated albumin and glomerular anionic charges.
abstract: Aiming to discern the mechanisms by which circulating glycated albumin alters the glomerular filtration properties that lead to glomerular dysfunction in diabetes, the authors studied the distribution and densities of anionic charges through the rat glomerular wall upon intravascular infusion of Amadori products, as well as in various conditions of increased glomerular permselectivity. Polylysine-gold was used as the probe to reveal the anionic charges. The study was carried on renal tissue sections of bovine serum albumin (BSA)- and glycated BSA-injected, normoglycemic animals. Results were generated through morphometrical evaluations of the gold labeling. Changes in glomerular anionic distribution were corroborated on renal tissue sections of short- and long-term diabetic rats and of normal newborn rats, situations known for abnormal glomerular filtration. Altered renal function in these conditions was clearly associated with changes in glomerular anionic charges. On the other hand, the infusion of glycated albumin in the circulation of normal rats, though altering glomerular filtration properties, did not modify the distribution and density of the polylysine-gold labeling through the glomerular basement membrane. Thus, anionic charges seem not to be the factor involved in the early changes of glomerular permeability induced by circulating glycated albumin.
authors: Department of Pathology and Cell Biology, Université de Montréal, Montreal, Quebec, Canada.
authors: I
authors: I
authors: Londoño
authors: D
authors: D
authors: Gingras
authors: M
authors: M
authors: Bendayan
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001485:Basement Membrane / Q000187:drug effects / Q000502:physiology; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology*; D017127:Glycation End Products, Advanced; D007275:Injections, Intravenous; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D012709:Serum Albumin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D012710:Serum Albumin, Bovine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000093423:Glycated Serum Albumin
chemical_list: D017127:Glycation End Products, Advanced; D012709:Serum Albumin; D012710:Serum Albumin, Bovine; D000093423:Glycated Serum Albumin